Shiji Biotechnology
SciGene produces and markets automated instruments for genomic research labs, reducing expenses and improving result accuracy
About Shiji Biotechnology
SciGene specializes in automating workflows for cytogenetic laboratories, focusing on reducing costs and enhancing the reliability of assay results. The company operates in the cytogenetics market, serving laboratories that require precise and efficient preparation of chromosome slides for various analyses such as G banding and FISH (Fluorescence In Situ Hybridization). SciGene's core products include the Scorpion Slide Preparation Robot and the Little Dipper Processor, which automate the preparation and banding of slides, respectively. These products are designed to improve the efficiency and accuracy of cytogenetic assays by automating time-consuming manual processes. SciGene's business model revolves around selling these specialized robotic systems and related consumables, such as CytoDrop Slides, which are engineered to provide uniformly wettable surfaces for optimal sample spreading. The company generates revenue through the sale of these products and potentially through service agreements for maintenance and support. SciGene's clients are primarily clinical and research laboratories that require high-quality cytogenetic analysis with fast turnaround times. The company's market includes both domestic and international laboratories that perform karyotyping and other chromosome analyses.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- Sunnyvale, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SECONDARYOther financing | Feb 2024 | $227M | $756M | Tongwei Group | ↗ |
| LATE VCOther financing | Sep 2023 | $55M | $275M | CICC · Anhui State Control | ↗ |
Growth signals
Latest recorded traffic for Shiji Biotechnology is 2.5K monthly website visits, up 38.9% over the last three months. Shiji Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
CICC- ACAnhui State Control
Tongwei Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shiji Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shiji Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







